

Letters

RESEARCH LETTER

Myocarditis Following COVID-19 BNT162b2 Vaccination Among Adolescents in Hong Kong

Cases of myocarditis following the second dose of messenger RNA (mRNA) vaccine are accruing worldwide, especially in younger male adults and adolescents.¹⁻⁴ In weighing the risk of myocarditis against the benefit of preventing severe COVID-19, Norway, the UK, and Taiwan have suspended the second dose of mRNA vaccine for adolescents. Similarly, adolescents (aged 12-17 years) in Hong Kong have been recommended to receive 1 dose of BNT162b2 instead of 2 doses 21 days apart since September 15, 2021 (Figure).

Methods | This cohort study was conducted before the arrival of the Omicron variant. We linked vaccination records with the Hong Kong territorywide electronic health record database through government-commissioned population-based COVID-19 vaccine safety surveillance.³ Among adolescents who received at least 1 dose of BNT162b2 between March 10 and October 18, 2021, inpatient myocarditis cases were identified using the *International Classification of Diseases, Ninth Revision, Clinical Modification* (422.x and 429.0). Adolescents with a history of myocarditis were excluded. The study was approved by the institutional review board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster and the Department of Health Ethics Committee with a waiver of informed consent because anonymized data were used. The statistical tests are described in the eMethods in the Supplement. This study followed the Strengthening of Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.

Results | A total of 224 560 first doses and 162 518 second doses of BNT162b2 were administered to adolescents. Forty-three adolescents had myocarditis-related hospitalization following receipt of BNT162b2 vaccination, and 84% of the hospitalizations (36 of 43) occurred after the second dose. The incidence rate was 3.12 (95% CI, 1.25-6.42) and 22.15 (95% CI,

15.51-30.67) per 100 000 persons for the first and second dose, respectively (Table). The number needed to harm for the first and second dose were 32 051 and 4515, respectively. The crude risk ratio of the second dose vs first dose was 7.11 (95% CI, 3.16-15.97). The cumulative incidence of myocarditis decreased from 43 cases in 202 315 adolescents vaccinated (21.25, 95% CI, 15.38-28.63) per 100 000 persons to 0 cases in 22 245 adolescents vaccinated at implementation of the single-dose policy. The 40 167 prepolicy first dose recipients did not receive the second dose because of the single-dose policy. Based on the number needed to harm of the second dose, an estimated 8.90 (95% CI, 6.23-12.32) myocarditis cases were prevented.

Discussion | In this cohort study, the single-dose regimen was found to be associated with reduction in myocarditis risk among vaccinated adolescents. Limitations include sample size during the postpolicy period. Since May 2021, no local transmission of SARS-CoV-2 has occurred in Hong Kong, with stringent nonpharmaceutical interventions. Among the 343 700 adolescents in Hong Kong, no COVID-19-related death has been reported, and the only one admitted to the pediatric intensive care unit due to COVID-19 was an imported case,⁵ indicating that the risk of death or complications from COVID-19 is extremely low among adolescents in Hong Kong. Vaccination policy for adolescents should consider the trade-off between risks and benefits. In countries with large outbreaks and to prevalent local transmission, the risk-benefit assessment would favor a 2-dose regimen because the single-dose regimen provides suboptimal protection from severe outcomes associated with COVID-19. However, in settings with no evident local transmission and stringent infection control policies, single-dose mRNA vaccination might be a viable option for offering protection to adolescents from severe outcomes associated with COVID-19.

Nevertheless, questions remain about the mechanism of myocarditis following mRNA vaccine. Potential ways to reduce myocarditis risk in adolescents could be the use of single-dose only, a lower dosage for 2 doses as recommended for children aged 5 to 11 years,⁶ or a lengthened interval between doses. More laboratory, trial, and postmarketing data may become

Figure. Timeline of BNT162b2 Vaccination Policy Among Adolescents in Hong Kong




Table. Myocarditis Cases Following the BNT162b2 Vaccination Among 43 Adolescents in Hong Kong Before and After the Single-Dose Policy

Variable	Male (n = 38 [88%])	Female (n = 5 [12%])	Total (n = 43 [100%])
Age, mean (SD), y	14.95 (1.35)	14.20 (2.17)	14.86 (1.46)
Before single-dose recommendation			
Cases, No.	38	5	43
Doses administered, total No.	181 392	177 405	358 797
Adolescents who received vaccination, total No.	102 242	100 073	202 315
After single-dose recommendation			
Cases, No.	0	0	0
Doses administered, total No.	14 386	13 895	28 281
Adolescents who received vaccination, total No.	11 525	10 720	22 245
Overall observational period			
Cases after first dose, No./recipients of first dose, total No.	6/113 767	1/110 793	7/224 560
Incidence after first dose per 100 000 persons (95% CI)	5.27 (1.94-11.48)	0.90 (0.023-5.03)	3.12 (1.25-6.42)
NNH for the first dose (95% CI)	18 975 (8711-51 546)	111 111 (19 881-4 347 826)	32 051 (15 576-80 000)
Cases after second dose, No./recipients of second dose, total No.	32/82 011	4/80 507	36/162 518
Incidence after second dose per 100 000 persons (95% CI)	39.02 (26.69-55.08)	4.97 (1.35-12.72)	22.15 (15.51-30.67)
NNH for the second dose (95% CI)	2563 (1816-3747)	20 121 (7862-74 074)	4515 (3261-6447)

Abbreviation: NNH, number needed to harm.

available to answer these questions. Our study expands the current understanding of dose-response relationship and suggests that COVID-19 vaccination recommendations in adolescents may need to be customized rather than standardized to fit all.

Xue Li, PhD
Francisco Tsz Tsun Lai, PhD
Gilbert T. Chua, MBBS
Mike Yat Wah Kwan, MSc
Yu Lung Lau, MD
Patrick Ip, MPH, MBBS
Ian Chi Kei Wong, PhD

Author Affiliations: Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong (Li); Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong (Lai, Wong); Department of Paediatrics and Adolescent Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong (Chua, Lau, Ip); Department of Paediatrics and Adolescent Medicine, Princess Margaret Hospital, Hong Kong (Kwan).

Accepted for Publication: December 29, 2021.

Published Online: February 25, 2022. doi:10.1001/jamapediatrics.2022.0101

Open Access: This is an open access article distributed under the terms of the [CC-BY License](#). © 2022 Li X et al. *JAMA Pediatrics*.

Corresponding Authors: Ian Chi Kei Wong, PhD, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, University of Hong Kong; L2-57, Laboratory Block, 21 Sassoon Rd, Pok Fu Lam, The University of Hong Kong (wongjck@hku.hk); Patrick Ip, MPH, Department of Paediatrics and Adolescent Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong; Room 115, New Clinical Building, Queen Mary Hospital, 102 Pok Fu Lam Rd, Hong Kong (patricip@hku.hk).

Author Contributions: Dr Wong had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs Li, Lai, and Chua contributed equally as co-first authors.

Concept and design: Li, Kwan, Lau, Ip, Wong.

Acquisition, analysis, or interpretation of data: Li, Lai, Chua, Kwan, Ip, Wong.

Drafting of the manuscript: Li, Lai, Chua, Kwan.

Critical revision of the manuscript for important intellectual content: Lai, Chua, Kwan, Lau, Ip, Wong.

Statistical analysis: Li, Lai, Kwan.

Obtained funding: Wong.

Administrative, technical, or material support: Li, Chua, Kwan, Ip.

Supervision: Kwan, Lau, Ip, Wong.

Conflict of Interest Disclosures: Dr Li reported receiving grants from Research Grant Council/Early Career Scheme, Health and Medical Research Fund, Pfizer, Janssen, University of Hong Kong, and personal fees from Merck Sharp & Dohme outside the submitted work. Dr Wong reported receiving grants from Food and Health Bureau, The Government of the Hong Kong Special Administrative Region COVID19F01 during the conduct of the study; and research funding outside the submitted work from Amgen, Bristol-Myers Squibb, Pfizer, Janssen, Bayer, GSK, Novartis, Takeda, the Hong Kong Research Grants Council, the Hong Kong Health and Medical Research Fund, National Institute for Health Research in England, European Commission, National Health and Medical Research Council in Australia, and receiving speaker fees from Janssen and Medice in the previous 3 years. The posts of Drs Wong and Lai were partly funded by The Laboratory of Data Discovery for Health (D24H); hence this work was partly supported by AIR@InnoHK administered by Innovation and Technology Commission. No other disclosures were reported.

Funding/Support: This study was regulatory-initiated pharmacovigilance and was funded by a research grant from the Food and Health Bureau of The Government of the Hong Kong Special Administrative Region (COVID19F01).

Role of the Funder/Sponsor: The funding organization provided record-linkage data via the Department of Health and Hospital Authority but has no role in the design and conduct of the study. The funding organization had no role in the management, analysis, and interpretation of the data. The funding organization reviewed and approved the manuscript but had no role in the preparing of the manuscript nor the decision to submit the manuscript for publication.

Additional Contributions: We appreciate the contributions of other investigators to the development of the COVID-19 Vaccines Adverse Events Response and Evaluation (CARE) Programme and the finalization of this study. We thank colleagues from the Drug Office of the Department of Health and the Hospital Authority for the generous provision of vaccination and clinical data. We thank Mr Kuan Peng (MHA, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, University of Hong Kong) and Ms Lei Huang (MSc, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, University of Hong Kong) for their assistance in data collection and analysis. We also thank Ms Lisa Lam (MJ, BSc, BA, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, University of Hong Kong) for proofreading the manuscript.

1. Witberg G, Barda N, Hoss S, et al. Myocarditis after COVID-19 vaccination in a large health care organization. *N Engl J Med*. 2021;385(23):2132-2139. doi:10.1056/NEJMoa2110737
2. Chua GT, Kwan MYW, Chui CSL, et al. Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents following comirnaty vaccination. *Clin Infect Dis*. 2021;ciab989. doi:10.1093/cid/ciab989
3. Diaz GA, Parsons GT, Gering SK, Meier AR, Hutchinson IV, Robicsek A. Myocarditis and pericarditis after vaccination for COVID-19. *JAMA*. 2021;326(12):1210-1212. doi:10.1001/jama.2021.13443
4. Lai FTT, Li X, Peng K, et al. Carditis after COVID-19 vaccination with a messenger RNA vaccine and an inactivated virus vaccine: a case-control study. *Ann Intern Med*. 2022. Published online January 25, 2022. doi:10.7326/M21-3700
5. Chua GT, Wong JSC, Lam I, et al. Clinical characteristics and transmission of COVID-19 in children and youths during 3 waves of outbreaks in Hong Kong. *JAMA Netw Open*. 2021;4(5):e218824-e218824. doi:10.1001/jamanetworkopen.2021.8824
6. Walter EB, Talaat KR, Sabharwal C, et al; C4591007 Clinical Trial Group. Evaluation of the BNT162b2 COVID-19 vaccine in children 5 to 11 years of age. *N Engl J Med*. 2022;386(1):35-46. doi:10.1056/NEJMoa2116298